
Coco Gauff is just 21 but already thinking about what to do after tennis
LONDON — To be clear, Coco Gauff didn't bring up the word 'star' during a recent interview with the Associated Press; the reporter did. So as Gauff began to answer a question about balancing her life as a professional athlete with her off-court interests, she caught herself repeating that term.
'I definitely didn't know how it would look like,' she began with a smile, 'before I got to be, I guess, a star — feels weird to call myself that — but I definitely did want to expand outside of tennis. Always. Since I was young.'
She still is young, by just about any measure, and she is a really good tennis player — Gauff owns the Grand Slam titles and No. 2 ranking to prove it as she heads into Wimbledon, which begins Monday — but the 21-year-old American is also more than that.
Someone unafraid to express her opinions about societal issues. Someone who connects with fans via social media. Someone who is the highest-paid female athlete in any sport, topping $30 million last year, according to Sportico.com, with less than a third of that from prize money and most via deals with companies such as UPS, New Balance, Rolex and Barilla. Someone who recently launched her own management firm.
And someone who wants to succeed in the business world long after she no longer swings a racket on tour.
'It's definitely something that I want to start to step up for post-career. Kind of start building that process, which is why I wanted to do it early. Because I didn't want to feel like I was playing catch-up at the end of my career,' said Gauff, who will face Dayana Yastremska in the first round at the All England Club on Tuesday.
'On the business side of things, it doesn't come as natural as tennis feels. I'm still learning, and I have a lot to learn about,' Gauff said. 'I've debated different things and what paths I wanted to take when it came to just stimulating my brain outside of the court, because I always knew that once I finished high school that I needed to put my brain into something else.'
In a campaign announced this week by UPS, which first partnered with Gauff in 2023 before she won that year's U.S. Open, she connects with business coach Emma Grede — known for working with Kim Kardashian on Skims, and with Khloe Kardashian on Good American — to offer mentoring to three small-business owners.
'Coco plays a key role in helping us connect with those younger Gen-Z business owners — emerging or younger entrepreneurs,' Betsy Wilson, vice president of digital marketing and brand activation at UPS, said in a phone interview. 'Obviously, she's very relevant in social media and in culture, and working with Coco helps us really connect with that younger group.'
While Grede helped the entrepreneurs, Gauff also got the opportunity to pick up tips.
'It's really cool to learn from someone like her,' Gauff said. 'Whenever I feel like I'm ready to make that leap, I can definitely reach out to her for advice and things like that. ... This will help me right now and definitely in the long term.'
Fendrich writes for the Associated Press.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Raducanu, Alcaraz, Boulter and heat - Monday's Wimbledon preview
Emma Raducanu has a prime Court One slot for her all-British Wimbledon opener [Getty Images] Wimbledon 2025 Dates: 30 June-13 July Venue: All England Club Coverage: Live across BBC TV, radio and online with extensive coverage on BBC iPlayer, Red Button, Connected TVs and mobile app. Wimbledon starts on Monday as the first contingent of the 23 British players in men's and women's singles compete on the All England Club grass courts. British involvement in the singles is at its highest since 1984, with 14 home players involved on day one of the 138th Championships. Among them will be Katie Boulter and Emma Raducanu, handed prime show-court slots. Advertisement Two-time defending men's champion Carlos Alcaraz begins his campaign on Monday, as does women's world number one Aryna Sabalenka. Prepare for a sunny sizzler of a day. The weather forecast points to temperatures climbing as high as 33C in south-west London, so the heat presents a challenge in itself for the players. [BBC] As Wimbledon tradition dictates, men's champion Alcaraz opens play on Centre Court. The second seed launches his campaign at 13:30 BST as he faces 38-year-old Italian Fabio Fognini. That is followed by Briton Boulter's match against Spanish ninth seed Paula Badosa before German third seed Alexander Zverev faces France's Arthur Rinderknech. Advertisement On Court One, Belarusian top seed Sabalenka gets play under way against Canadian Carson Branstine at 13:00 BST. Branstine, 24, got past French Open semi-finalist Lois Boisson and former US Open winner Bianca Andreescu in qualifying and will be making her main draw debut in a Grand Slam. Briton Jacob Fearnley takes on exciting Brazilian teenager Joao Fonseca in the second match on that court, before the intriguing all-British tie between Emma Raducanu and Mimi Xu, a 17-year-old from Swansea. [BBC] While Boulter, Fearnley, Raducanu and Xu start their tournaments on the main show courts, there will be 10 other Britons in action around the grounds, with play beginning at 11:00 BST. Advertisement Cameron Norrie, a semi-finalist three years ago, plays second on court 18 as he faces a tricky opponent in Spain's Roberto Bautista Agut. Sonay Kartal features in the court three opener against Latvian 20th seed and former French Open winner Jelena Ostapenko. The final two matches on court 17 feature British interest as Harriet Dart takes on Hungarian Dalma Galfi before world number 796 Mika Stojsavljevic faces American 31st seed Ashlyn Krueger. Stojsavljevic, 16, is a wildcard entry and won last year's US Open girls' title. Her fellow British 16-year-old Hannah Klugman is third on court 12 against Canada's Leylah Fernandez - the player Raducanu beat in the 2021 US Open final. Klugman, who was brought up in Wimbledon Village, reached the girls' final at the French Open in June. Advertisement British world number 719 Oliver Tarvet makes his Wimbledon debut against Swiss Leandro Riedi in the opening match on court four. Having come through qualifying, Tarvet is in the unfortunate position of not being able to claim all the prize money he would be due because of rules implemented in the US collegiate system. The fourth match on court four features Henry Searle - Britain's 2023 boys' Wimbledon champion - playing American Ethan Quinn. British world number 465 Arthur Fery takes on Australian 20th seed Alexei Popyrin, on Court 15 - followed by Billy Harris' match with Serbian Dusan Lajovic. Oliver Crawford, who was born in the US to British parents, makes his Grand Slam debut at the age of 26 against Italian Mattia Bellucci on court 16. Advertisement [BBC] As ever on the opening days of Wimbledon, it is not just the two main courts that get the star names. Four top-10 players feature on court two, starting with Russian former US Open winner Daniil Medvedev taking on France's Benjamin Bonzi. Reigning Australian Open champion Madison Keys plays second on the court as the American faces Elena-Gabriela Ruse of Romania. Jasmine Paolini of Italy became a crowd favourite on her run to last year's final. She begins her campaign this time against Latvian Anastasija Sevastova, while last on the same court is American Taylor Fritz, fresh from his run to a fourth Eastbourne title, as he plays France's Giovanni Mpetshi Perricard. Advertisement It could be late in the day when the Czech Republic's 2023 Wimbledon champion Marketa Vondrousova starts her quest on court 12 against American McCartney Kessler, winner of the Nottingham Open. Tunisia's two-time Wimbledon finalist Ons Jabeur gets play under way on court 14, taking on Viktoriya Tomova of Bulgaria, while four-time Grand Slam champion Naomi Osaka of Japan is last on court 18 against Australian Talia Gibson. [BBC] 10:30-19:00 - Live coverage - BBC Two, BBC iPlayer, BBC Sport website and app 11:00-21:30 - Live coverage of outside courts - BBC Red Button, BBC iPlayer, BBC Sport website and app Advertisement 12:30-22:00 - Live coverage - BBC Radio 5 Live, BBC Sounds app and BBC Sport website 14:00-18:00 - Live coverage - BBC One, BBC iPlayer, BBC Sport website and app 19:00-22:00 - Live coverage - BBC One, BBC iPlayer, BBC Sport website and app 23:55-00:55 - Today at Wimbledon - BBC Two
Yahoo
an hour ago
- Yahoo
Analog Devices' (NASDAQ:ADI) 16% CAGR outpaced the company's earnings growth over the same five-year period
Passive investing in index funds can generate returns that roughly match the overall market. But the truth is, you can make significant gains if you buy good quality businesses at the right price. For example, the Analog Devices, Inc. (NASDAQ:ADI) share price is 95% higher than it was five years ago, which is more than the market average. Zooming in, the stock is up just 3.8% in the last year. On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During five years of share price growth, Analog Devices achieved compound earnings per share (EPS) growth of 4.2% per year. This EPS growth is slower than the share price growth of 14% per year, over the same period. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth. This optimism is visible in its fairly high P/E ratio of 64.21. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). Dive deeper into Analog Devices' key metrics by checking this interactive graph of Analog Devices's earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Analog Devices, it has a TSR of 114% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. Analog Devices shareholders gained a total return of 5.6% during the year. Unfortunately this falls short of the market return. On the bright side, the longer term returns (running at about 16% a year, over half a decade) look better. It's quite possible the business continues to execute with prowess, even as the share price gains are slowing. It's always interesting to track share price performance over the longer term. But to understand Analog Devices better, we need to consider many other factors. Case in point: We've spotted 1 warning sign for Analog Devices you should be aware of. But note: Analog Devices may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data
Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its 'Buy' rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist's move followed Eli Lilly's presentation at the American Diabetes Association (ADA) 85th Annual Meeting. Pixabay/Public Domain The rating pertains to Eli Lilly's oral diabetes drug, orforglipron (OFG), evaluated in the Phase 3 ACHIEVE-1 study for Type 2 diabetes treatment. The ACHIEVE-1 study results were presented at the ADA conference, showcasing orforglipron's efficacy and safety profile. The trial demonstrated statistically significant reductions in A1C (a long-term blood sugar metric) and body weight compared to placebo, with efficacy increasing at higher doses. Truist's analysis was informed by attending the orforglipron presentation, gathering feedback from KOLs at the ADA conference, and participating in Eli Lilly's investor event, where management provided clarity to alleviate safety concerns. The firm noted that longer-term data are required to further strengthen orforglipron's safety profile, particularly for chronic use in diabetes and potential obesity indications. Eli Lilly and Company (NYSE:LLY) is an American global biopharmaceutical company. The company discovers, develops, and markets prescription medicines for diabetes, obesity, cancer, immunological disorders, and neurological diseases. Its key products include Mounjaro, Zepbound, Trulicity, Verzenio, Taltz, and Jardiance. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.